Status:
COMPLETED
This is a Study to Determine the Antidepressant Effects of AZD6765
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Conditions:
Treatment Resistant Major Depressive Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the antidepressant effects of AZD6765 compared to placebo.
Eligibility Criteria
Inclusion
- Patients with a diagnosis of Major Depressive Disorder, currently depressed without psychotic features
- Females must be of non-childbearing potential.
Exclusion
- Treatment with Clozapine or ECT within 3 months prior to study
- Current or past history of psychotic features or a diagnosis of schizophrenia or any other psychotic disorder as defined in the DSM-IV
Key Trial Info
Start Date :
December 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00986479
Start Date
December 1 2009
End Date
December 1 2011
Last Update
October 21 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Bethesda, Maryland, United States